77 related articles for article (PubMed ID: 10978778)
1. KRN5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts.
Stine KC; Warren BA; Saylors RL; Becton DL
Leuk Res; 2000 Sep; 24(9):741-9. PubMed ID: 10978778
[TBL] [Abstract][Full Text] [Related]
2. Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein.
Zhang WJ; Ohnishi K; Yoshida H; Pan L; Maksumova L; Muratkhodjaev F; Luo JM; Shigeno K; Fujisawa S; Naito K; Nakamura S; Shinjo K; Takeshita A; Ohno R
Jpn J Cancer Res; 2000 Jun; 91(6):604-11. PubMed ID: 10874212
[TBL] [Abstract][Full Text] [Related]
3. KRN5500, a novel antitumor agent, induces apoptosis or cell differentiation in HL-60 cells.
Kawasaki K; Murakami T; Ita M; Sasaki K; Furukawa S
Cytometry; 2000 Mar; 39(3):211-6. PubMed ID: 10685078
[TBL] [Abstract][Full Text] [Related]
4. KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.
Miki H; Ozaki S; Nakamura S; Oda A; Amou H; Ikegame A; Watanabe K; Hiasa M; Cui Q; Harada T; Fujii S; Nakano A; Kagawa K; Takeuchi K; Yata K; Sakai A; Abe M; Matsumoto T
Br J Haematol; 2011 Nov; 155(3):328-39. PubMed ID: 21902681
[TBL] [Abstract][Full Text] [Related]
5. KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.
Byrd JC; Lucas DM; Mone AP; Kitner JB; Drabick JJ; Grever MR
Blood; 2003 Jun; 101(11):4547-50. PubMed ID: 12595316
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
7. [Spicamycin derivative].
Mizumura Y
Nihon Rinsho; 2006 Feb; 64(2):322-8. PubMed ID: 16454188
[TBL] [Abstract][Full Text] [Related]
8. In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model.
Kanzawa F; Nishio K; Fukuoka K; Sunami T; Saijo N
Cancer Chemother Pharmacol; 1999; 43(5):353-63. PubMed ID: 10100589
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.
Kamishohara M; Kawai H; Sakai T; Isoe T; Hasegawa K; Mochizuki J; Uchida T; Kataoka S; Yamaki H; Tsuruo T
Oncol Res; 1994; 6(8):383-90. PubMed ID: 7894087
[TBL] [Abstract][Full Text] [Related]
10. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells.
Bhalla K; Ibrado AM; Tourkina E; Tang C; Mahoney ME; Huang Y
Leukemia; 1993 Apr; 7(4):563-8. PubMed ID: 8096557
[TBL] [Abstract][Full Text] [Related]
11. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells.
Bhalla K; Ibrado AM; Tourkina E; Tang C; Grant S; Bullock G; Huang Y; Ponnathpur V; Mahoney ME
Blood; 1993 Nov; 82(10):3133-40. PubMed ID: 8219202
[TBL] [Abstract][Full Text] [Related]
12. Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500.
Kamishohara M; Kenney S; Domergue R; Vistica DT; Sausville EA
Exp Cell Res; 2000 May; 256(2):468-79. PubMed ID: 10772819
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors.
Yamamoto N; Tamura T; Kamiya Y; Ono H; Kondoh H; Shirao K; Matsumura Y; Tanigawara Y; Shimada Y
Jpn J Clin Oncol; 2003 Jun; 33(6):302-8. PubMed ID: 12913085
[TBL] [Abstract][Full Text] [Related]
14. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis.
Garrido SM; Cooper JJ; Appelbaum FR; Willman CL; Kopecky K; Banker DE
Leuk Res; 2001 Jan; 25(1):23-32. PubMed ID: 11137557
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study.
Takama H; Tanaka H; Sudo T; Tamura T; Tanigawara Y
Cancer Chemother Pharmacol; 2001 May; 47(5):404-10. PubMed ID: 11391855
[TBL] [Abstract][Full Text] [Related]
16. [Effect of WT1 antisense oligonucleotide on proliferation and apoptosis of human leukemia cells].
Wu X; Wang Y; Pei X
Zhonghua Xue Ye Xue Za Zhi; 1999 Dec; 20(12):631-3. PubMed ID: 11721364
[TBL] [Abstract][Full Text] [Related]
17. The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein.
Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
Jpn J Cancer Res; 2000 Feb; 91(2):248-54. PubMed ID: 10761713
[TBL] [Abstract][Full Text] [Related]
18. A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial.
Weinstein SM; Abernethy AP; Spruill SE; Pike IM; True Kelly A; Jett LG
J Pain Symptom Manage; 2012 Apr; 43(4):679-93. PubMed ID: 21983265
[TBL] [Abstract][Full Text] [Related]
19. Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP).
Yinjun L; Jie J; Weilai X; Xiangming T
Am J Hematol; 2004 Jul; 76(3):199-204. PubMed ID: 15224352
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.
Gambacorti-Passerini C; le Coutre P; Mologni L; Fanelli M; Bertazzoli C; Marchesi E; Di Nicola M; Biondi A; Corneo GM; Belotti D; Pogliani E; Lydon NB
Blood Cells Mol Dis; 1997 Dec; 23(3):380-94. PubMed ID: 9446752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
